Australia markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.8700-0.4300 (-10.00%)
At close: 04:00PM EDT
3.8400 -0.03 (-0.78%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 440.34M
Enterprise value 228.70M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.99
Price/book (mrq)1.20
Enterprise value/revenue 3.60
Enterprise value/EBITDA -1.33

Trading information

Stock price history

Beta (5Y monthly) 1.68
52-week change 3-36.24%
S&P500 52-week change 321.08%
52-week high 38.8300
52-week low 31.6300
50-day moving average 36.7076
200-day moving average 34.0791

Share statistics

Avg vol (3-month) 32.8M
Avg vol (10-day) 32.59M
Shares outstanding 5113.78M
Implied shares outstanding 6113.78M
Float 880.65M
% held by insiders 11.47%
% held by institutions 193.92%
Shares short (15 Apr 2024) 418.92M
Short ratio (15 Apr 2024) 47.34
Short % of float (15 Apr 2024) 420.55%
Short % of shares outstanding (15 Apr 2024) 416.63%
Shares short (prior month 15 Mar 2024) 413.16M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -253.30%
Operating margin (ttm)-2,098.75%

Management effectiveness

Return on assets (ttm)-18.32%
Return on equity (ttm)-37.76%

Income statement

Revenue (ttm)63.53M
Revenue per share (ttm)0.65
Quarterly revenue growth (yoy)-96.20%
Gross profit (ttm)N/A
EBITDA -159.33M
Net income avi to common (ttm)-160.93M
Diluted EPS (ttm)-1.6400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)315.18M
Total cash per share (mrq)3.18
Total debt (mrq)103.54M
Total debt/equity (mrq)28.10%
Current ratio (mrq)8.48
Book value per share (mrq)3.73

Cash flow statement

Operating cash flow (ttm)-132.26M
Levered free cash flow (ttm)-74.25M